Viewing Study NCT01268150

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 5:08 PM

Ignite Modification Date: 2025-12-27 @ 9:55 PM

Study NCT ID: NCT01268150

Status: COMPLETED

Last Update Posted: 2023-06-22

First Post: 2010-12-28

Is NOT Gene Therapy: True

Has Adverse Events: True

Brief Title: A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Sponsor: Eisai Inc.

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module Adverse Events Module Baseline Characteristics Module Participant Flow Module